Aurinia Pharmaceuticals Inc
AUPHAurinia Pharmaceuticals Inc. is a global biotechnology company focused on the development and commercialization of therapies for autoimmune and inflammatory diseases. The company's flagship product, Lupkynis, is approved for the treatment of lupus nephritis, a serious complication of systemic lupus erythematosus. Aurinia specializes in innovative treatments targeting immune system pathways to address unmet medical needs.
Company News
The American College of Rheumatology has updated its guidelines for treating lupus nephritis, recommending early use of triple therapy (mycophenolate mofetil, glucocorticoids, and either Benlysta or a calcineurin inhibitor). However, current practice often delays initiating triple therapy until initial treatment failure.
The American Kidney Fund's Disaster Relief Program is providing emergency financial assistance to dialysis and recent transplant patients in areas affected by Hurricane Helene. The program has received generous support from various companies and individual donors to help cover expenses related to lost medications, housing, transportation, and per...
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The average of price targets set by Wall Street analysts indicates a potential upside of 96.5% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Aurinia (AUPH) delivered earnings and revenue surprises of 82.35% and 8.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
